SEC Filing Analysis: ACCURAY INC (ARAY)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: A director was granted restricted stock representing approximately 0.31% of the company's total shares outstanding, a notable equity award for a small-cap company.
• Market Impact: The grant introduces potential future dilution for existing shareholders upon vesting.

Company Information

Field	Value
Company	ACCURAY INC
Ticker Symbol	ARAY
CIK	0001138723
Industry	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]

Insider Information

Field	Value
Name	MAYER STEVEN F
CIK	0001280289
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-31
Transaction Code	A (Award)
Security Type	Common Stock
Shares Involved	354,609
Price Per Share	$0.0
Total Value	$0.0
Shares Owned After	354,609
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.0
% of Market Cap	0.0%
Shares Transacted	354,609
% of Shares Outstanding	0.315%
Post-Transaction Ownership	354,609 shares (0.315% of outstanding)
Materiality Assessment	Moderate

Impact Evaluation

• Market Cap Context: For Accuray, a company with a market capitalization of $160 million, equity grants are a common tool to conserve cash while compensating leadership. However, their dilutive effect is more pronounced in smaller companies.
• Ownership Concentration: This grant establishes the director's initial direct holding in the company, aligning their financial interests with those of shareholders.
• Dilution Impact: The 354,609 shares granted represent approximately 0.315% of the total shares outstanding. While not exceeding the 0.5% threshold for high significance, this is a moderately dilutive event from a single award to one individual, which existing shareholders should note.
• Transaction Significance: The significance is rated 'Medium' not due to the dollar value (which is $0 for a grant), but because of the notable percentage of shares outstanding being issued as compensation. This impacts the ownership structure and represents a future supply of shares post-vesting.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Stock grants are a routine form of compensation. While the size is notable relative to the company's outstanding shares, it is not an open-market transaction and is unlikely to cause an immediate, significant price reaction. The market has likely priced in such compensation practices.

Volume & Sentiment

• Expected Volume Impact: Minimal to none. As this is not a market transaction, it will not directly impact trading volume.
• Sentiment Indicator: Neutral. This filing is informational and reflects standard corporate governance practices regarding compensation.

Investment Insights

Positive Market Indicators

• The grant aligns the director's interests with shareholders, as the value of their compensation is tied to the company's future stock performance.

Risk Factors

• The award contributes to shareholder dilution. The 0.315% dilution from this single grant, while moderate, adds to the cumulative effect of the company's overall equity compensation program.

Key Takeaways

1. Director Compensation: A director received a significant equity award of 354,609 restricted shares.
2. Shareholder Dilution: The grant represents ~0.31% of total shares outstanding, a moderately dilutive event for a small-cap company.
3. Future Vesting: The shares are scheduled to vest entirely on the one-year anniversary of the grant date, at which point they could be sold on the open market, potentially adding to supply.

Additional Context

Transaction Notes

• Special Circumstances: The filing's footnote confirms this is an award of restricted stock under the company's 2016 Equity Incentive Plan, with 100% of shares vesting after one year.